Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Bibliographic Details
Title:	Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia
Authors:	Marconi, Giovanni, Piciocchi, Alfonso ^, Audisio, Ernesta ^, Priolo, Giorgio ^, Papayannidis, Cristina, Martelli, Maurizio ^, Paoloni, Francesca ^, Lemoli, Roberto Massimo ^, Bocchia, Monica ^, Lanza, Francesco ^, Lico, Albana ^, Ciceri, Fabio ^, Della Porta, Matteo G. ^, Frigeni, Marco ^, Giaccone, Luisa ^, Beltrami, Germana ^, Borlenghi, Erika ^, Di Chio, Maria Chiara ^, Selleri, Carmine, Crea, Enrico ^, Urbino, Irene ^, Sartor, Chiara ^, Minotti, Clara ^, Guolo, Fabio ^, La Sala, Edoardo ^, Nanni, Jacopo ^, Simonetti, Giorgia ^, Bochicchio, Maria Teresa ^, Saglio, Giuseppe, Venditti, Adriano, Vignetti, Marco ^, Fazi, Paola ^*, Martinelli, Giovanni
Source:	In Blood 15 November 2022 140 Supplement 1:1705-1707
Database:	ScienceDirect